Cryoport has formed a strategic partnership with fertility technology company TMRW Life Sciences to provide fertility clinics with temperature-controlled management and transport solutions in the US.
The partnership follows increased demands for secure shipping solutions at cryogenic temperatures. Cryoport will lead the transportation of the specimens between TMRW biorepositories and fertility clinics.
At cryogenic temperatures, the specimens are protected from further ageing or damage.
Louis Villalba, CEO of TMRW, said, “Cryoport’s reputation for excellence in reproductive biologistics, paired with TMRW’s cutting-edge specimen management technology and safety certifications, delivers security and peace of mind for transporting specimens in the fertility space.”
Cryoport has over a decade of experience in reproductive medicine biologistics. Additionally, TMR is the only reproductive health storage provider with HIPAA-compliant, military-grade data security with SOC II and HITRUST certifications. Both TMRW and Cryoport are ISO-certified.
Dr. Mark Sawicki, President and CEO of Cryopoprt, said the organisations share a mutual focus on derisking processes, innovation, and quality.
“By combining forces and bringing our solutions and expertise to this endeavour, we can offer unmatched end-to-end solutions for the safe transport, management, and storage of frozen eggs, embryos, and sperm.”
According to market research, the US fertility market size is calculated at $5.71bn in 2024 and is expected to achieve around $8.69bn by 2033, growing at a CAGR of 4.78% between 2024 and 2033.
News of Cryoport’s partnership with TMRW follows a separate deal with VGXI, a subsidiary of GeneOne Life Science, to support the development of cell and gene therapies and mRNA-based treatments.
Read more: Cryoport and VGXI partner to advance cell and gene therapy supply chain
Under terms of the deal, Cryoport will provide biostorage and bioservices for plasmid DNA products manufactured at VGXI’s facilities in the Woodlands, Texas, and its headquarters and manufacturing location, also in Texas.
Cell and gene therapies also require a robust shipping system at cryogenic temperatures that can handle the risks associated with transporting high-value commodities such as advanced therapies. Slight temperature deviations can render the commodity ineffective, and minor physical damage can also damage its usability.
gasworld Yearbook
The gasworld Yearbook is an essential annual publication for the industrial gas sector, compiling key news, reports, and trend analysis from the past year. It covers developments across CO2, helium, air gases, hydrogen, LNG, and specialty gases, featuring market trends, technological advancements, significant mergers and acquisitions, and interviews with industry leaders.
With 12 months of exposure, advertising in gasworld’s Yearbook will help cement your company alongside the most significant new developments, technologies and solutions of the industrial gas year.
Get in touch with our sales team today to learn more.
